$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

$tnfa Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000149315223017488 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$3.557M	$1.057M	$1.492M
YoY Change	140.51%	-29.16%	-1.18%
% of Gross Profit
Research & Development	$2.224M	$770.4K	$2.630M
YoY Change	2.79%	-70.7%	-13248.7%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$2.224M	$770.4K	$4.122M
YoY Change	2.79%	-81.31%	176.63%
Operating Profit	-$5.782M	-$2.590M	-$4.122M
YoY Change	58.71%	-37.16%	176.63%
Interest Expense	-$1.317M	$1.199M	-$4.620K
YoY Change	-19100.29%	-26058.66%	-115.4%
% of Operating Profit
Other Income/Expense, Net	$1.614M	$1.079M	-$180.00
YoY Change	23176.31%	-599315.0%
Pretax Income	-$4.168M	-$1.512M	-$4.122M
YoY Change	14.62%	-63.33%	184.28%
Income Tax
% Of Pretax Income
Net Earnings	-$4.168M	-$1.512M	-$4.122M
YoY Change	14.62%	-63.33%	33.41%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.11	-$0.04	-$0.11
Diluted Earnings Per Share	-$0.11	-$0.04	-$108.1K
COMMON SHARES
Basic Shares Outstanding	39.61M shares	39.47M shares	38.12M shares
Diluted Shares Outstanding	40.35M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.63M	$15.55M	$9.188M
YoY Change	106.85%	69.22%	-70.41%
Cash & Equivalents	$93.82K	$188.5K	$1.189M
Short-Term Investments	$11.53M	$15.36M	$7.999M
Other Short-Term Assets	$1.516M	$738.1K	$884.1K
YoY Change	10.53%	-16.51%	301.87%
Inventory
Prepaid Expenses	$1.516M	$738.1K
Receivables
Other Receivables
Total Short-Term Assets	$13.14M	$16.29M	$10.07M
YoY Change	87.96%	61.7%	-70.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$107.6K	$123.8K	$132.8K
YoY Change	-36.81%	-6.73%
Goodwill	$10.50M	$10.50M
YoY Change	0.0%
Intangibles
YoY Change
Long-Term Investments	$1.500M	$1.500M	$1.500M
YoY Change	0.0%	0.0%
Other Assets
YoY Change
Total Long-Term Assets	$12.11M	$12.12M	$12.13M
YoY Change	-0.51%	-0.07%	708.75%
TOTAL ASSETS
Total Short-Term Assets	$13.14M	$16.29M	$10.07M
Total Long-Term Assets	$12.11M	$12.12M	$12.13M
Total Assets	$25.25M	$28.41M	$22.20M
YoY Change	31.77%	27.95%	-37.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.156M	$1.369M	$1.996M
YoY Change	-24.11%	-31.41%	-14.7%
Accrued Expenses	$497.4K	$169.9K	$470.7K
YoY Change	122.65%	-63.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$2.429M	$1.626M	$2.467M
YoY Change	-16.33%	-34.1%	4.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$11.32M	$12.78M	$114.6K
YoY Change	7997.24%	11048.8%
Total Long-Term Liabilities	$11.32M	$12.78M	$114.6K
YoY Change	7997.0%	11048.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.429M	$1.626M	$2.467M
Total Long-Term Liabilities	$11.32M	$12.78M	$114.6K
Total Liabilities	$13.75M	$14.40M	$2.581M
YoY Change	351.77%	457.92%	8.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$99.97M	-$95.43M
YoY Change	15.81%
Common Stock	$110.6M	$108.4M
YoY Change	8.09%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.74M	$13.09M	$19.62M
YoY Change
Total Liabilities & Shareholders Equity	$25.25M	$28.41M	$22.20M
YoY Change	31.77%	27.95%	-37.98%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$4.168M	-$1.512M	-$4.122M
YoY Change	14.62%	-63.33%	33.41%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$3.920M	-$3.972M	-$2.366M
YoY Change	9.86%	67.85%	-4.59%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$3.825M	-$11.27M	$2.999M
YoY Change	9.48%	-475.89%	-119.26%
Cash From Investing Activities	$3.825M	-$11.27M	$2.999M
YoY Change	9.48%	-475.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	$14.69M
YoY Change
NET CHANGE
Cash From Operating Activities	-3.920M	-$3.972M	-2.366M
Cash From Investing Activities	3.825M	-$11.27M	2.999M
Cash From Financing Activities	0.000	$14.69M
Net Change In Cash	-94.73K	-$560.5K	$0.00
YoY Change	27.91%
FREE CASH FLOW
Cash From Operating Activities	-$3.920M	-$3.972M	-$2.366M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001321834
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Other Liability Current Related And Nonrelated Party Status Extensible Enumeration OtherLiabilityCurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration	http://fasb.org/us-gaap/2023#RelatedPartyMember
CY2022Q4	us-gaap	Dividends Payable Current DividendsPayableCurrent		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	MYMD	Warrant Liability WarrantLiability		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022Q1	us-gaap	Revenue From Contract With Customer Product And Service Extensible List RevenueFromContractWithCustomerProductAndServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2022Q1	us-gaap	Type Of Cost Good Or Service Extensible List TypeOfCostGoodOrServiceExtensibleList	http://fasb.org/us-gaap/2023#ProductMember
CY2023Q1	MYMD	Uninsured Casualty Losses UninsuredCasualtyLosses		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
CY2023Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2022Q1	MYMD	Exercise Of Prepaid Equity Forward Contracts For Common Stock ExerciseOfPrepaidEquityForwardContractsForCommonStock		usd
CY2022Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022Q1	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability		usd
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2022Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2022Q1	us-gaap	Interest Paid Net InterestPaidNet		usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022Q1	MYMD	Accrual Of Series F Convertible Preferred Stock Dividend AccrualOfSeriesFConvertiblePreferredStockDividend		usd
CY2022Q1	MYMD	Initial Fair Value Of Warrant Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfWarrantLiabilitiesPursuantToIssuanceOfWarrants		usd
CY2022Q1	MYMD	Initial Fair Value Of Derivative Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfDerivativeLiabilitiesPursuantToIssuanceOfWarrants		usd
CY2022Q4	MYMD	Warrant Liability WarrantLiability		usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent		usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2023Q1	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod		shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q1	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled Or Expired In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledOrExpiredInPeriodWeightedAverageGrantDateFairValue
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-36268
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	MyMD Pharmaceuticals, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NJ
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	22-2983783
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	855 N. Wolfe Street
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 601
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Baltimore
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	21205
CY2023Q1	dei	City Area Code CityAreaCode	(856)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	848-8698
CY2023Q1	dei	Security12b Title Security12bTitle	Shares of Common Stock, no par value
CY2023Q1	dei	Trading Symbol TradingSymbol	MYMD
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	39605144	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	188548	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	749090	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15359954	usd
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	4086902	usd
CY2023Q1	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	738138	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	565787	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	16286640	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	5401779	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	123815	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139662	usd
CY2023Q1	us-gaap	Goodwill Goodwill	10498539	usd
CY2022Q4	us-gaap	Goodwill Goodwill	10498539	usd
CY2023Q1	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2022Q4	us-gaap	Long Term Investments LongTermInvestments	1500000	usd
CY2023Q1	us-gaap	Assets Noncurrent AssetsNoncurrent	12122354	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	12138201	usd
CY2023Q1	us-gaap	Assets Assets	28408994	usd
CY2022Q4	us-gaap	Assets Assets	17539980	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	1369200	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2673221	usd
CY2023Q1	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	29982	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	29982	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68004	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65780	usd
CY2023Q1	us-gaap	Dividends Payable Current DividendsPayableCurrent	158333	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1625519	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2768983	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58027	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75941	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3270500	usd
CY2023Q1	MYMD	Warrant Liability WarrantLiability	9448000	usd
CY2023Q1	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12776527	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	75941	usd
CY2023Q1	us-gaap	Liabilities Liabilities	14402046	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2844924	usd
CY2023Q1	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2022Q4	us-gaap	Preferred Stock No Par Value PreferredStockNoParValue	0
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2022Q4	us-gaap	Common Stock No Par Value CommonStockNoParValue	0
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39470009	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39470009	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39470009	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39470009	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	108378504	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	108309436	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95428969	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-93758904	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13094059	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28408994	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	17539980	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	987987	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1395112	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	770430	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2629741	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	69068	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	97000	usd
CY2023Q1	MYMD	Warrant Issuance Expenses WarrantIssuanceExpenses	762834	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2590319	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-4121853	usd
CY2023Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	25824	usd
CY2022Q1	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	120	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	175	usd
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1650	usd
CY2023Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-1712	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-3092	usd
CY2022Q1	MYMD	Uninsured Casualty Losses UninsuredCasualtyLosses	4442	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1175000	usd
CY2023Q1	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-120700	usd
CY2023Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1078587	usd
CY2022Q1	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-180	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1511732	usd
CY2022Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4122033	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1511732	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4122033	usd
CY2023Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	158333	usd
CY2023Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1670065	usd
CY2022Q1	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4122033	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.04
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	39787242	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	38122928	shares
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	14695056	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1511732	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	158333	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	69068	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13094059	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	23647174	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4122033	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	81002	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	15998	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	19622141	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1511732	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-4122033	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1175000	usd
CY2023Q1	MYMD	Change In Fair Value Of Derivative Liability ChangeInFairValueOfDerivativeLiability	-120700	usd
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	175	usd
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1650	usd
CY2023Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-1712	usd
CY2022Q1	us-gaap	Marketable Securities Gain Loss MarketableSecuritiesGainLoss	-3092	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	19908	usd
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81002	usd
CY2023Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	49160	usd
CY2022Q1	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	15998	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	172351	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-222226	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1304021	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1431487	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	157	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	396	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3971642	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2366182	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13024559	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	562	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1749970	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3000000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11274589	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2999438	usd
CY2023Q1	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	14685689	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	14685689	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-560542	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	633256	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	749090	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	555967	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	188548	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1189223	usd
CY2023Q1	MYMD	Accrual Of Series F Convertible Preferred Stock Dividend AccrualOfSeriesFConvertiblePreferredStockDividend	158333	usd
CY2023Q1	MYMD	Initial Fair Value Of Warrant Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfWarrantLiabilitiesPursuantToIssuanceOfWarrants	10623000	usd
CY2023Q1	MYMD	Initial Fair Value Of Derivative Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfDerivativeLiabilitiesPursuantToIssuanceOfWarrants	3149800	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_ztiMHrzvMIM1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(b) <span id="xdx_864_zJ0xJXc58gUe">Use of Estimates and Judgments</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with US GAAP requires management to make judgments, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected. Information about significant areas of estimation, uncertainty and critical judgments in applying accounting policies that have the most significant effect on the amounts recognized in the financial statements is included in the following notes for recording research and development expenses, impairment of intangible assets and the valuation of share-based payments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	175	usd
CY2022Q1	us-gaap	Marketable Securities Realized Gain Loss MarketableSecuritiesRealizedGainLoss	-1650	usd
CY2023Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	1749970	usd
CY2022Q1	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	3000000	usd
CY2023Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	13024559	usd
CY2022Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	562	usd
CY2023Q1	MYMD	Initial Fair Value Of Warrant Liability Pursuant To Private Placement InitialFairValueOfWarrantLiabilityPursuantToPrivatePlacement	10623000	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1175000	usd
CY2023Q1	MYMD	Warrant Liability WarrantLiability	9448000	usd
CY2023Q1	MYMD	Initial Fair Value Of Derivative Liability Pursuant To Private Placement InitialFairValueOfDerivativeLiabilityPursuantToPrivatePlacement	3149800	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	120700	usd
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	3270500	usd
CY2023Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_844_eus-gaap--ConcentrationRiskCreditRisk_zcv1KSRAUep6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(i) <span id="xdx_867_zOeqJHUF46s5">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash on deposit with financial institutions and accounts receivable. At times, the Company’s cash in banks is in excess of the FDIC insurance limit. The Company has not experienced any loss as a result of these cash deposits. These cash balances are maintained with three banks as of March 31, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	68004	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	65780	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	58027	usd
CY2022Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P12M
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	123815	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	139662	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	75941	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	19260	usd
CY2022Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	19461	usd
CY2023Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	18222	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P22Y
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.100	pure
CY2023Q1	MYMD	Lessee Operating Lease Liability Payments Due Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsDueRemainderOfFiscalYear	57902	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	74451	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	5814	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	138167	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	12136	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	126031	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2356555	usd
CY2023Q1	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2022Q1	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0	usd
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	27189465	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12443300	shares
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	169944	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	316666	usd
CY2023Q1	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1369200	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	2673221	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4476737	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2022Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.64
CY2023Q1	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	158333	usd
CY2023Q1	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	3149000	usd
CY2023Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	314311	usd
CY2023Q1	MYMD	Initial Fair Value Of Warrant Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfWarrantLiabilitiesPursuantToIssuanceOfWarrants	10623000	usd
CY2023Q1	us-gaap	Derivative Liabilities DerivativeLiabilities	120700	usd
CY2023Q1	MYMD	Initial Fair Value Of Warrant Liabilities Pursuant To Issuance Of Warrants InitialFairValueOfWarrantLiabilitiesPursuantToIssuanceOfWarrants	10623000	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	762834	usd
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	188548	usd
CY2023Q1	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15359954	usd
CY2023Q1	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1511732	usd
CY2023Q1	MYMD	Working Capital WorkingCapital	14661121	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	13094059	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-95428969	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3971642	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-1511732	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	172351	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1304021	usd
CY2023Q1	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-1175000	usd
CY2023Q1	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1199256	usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y7M20D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4476737	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	2.64
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue	2.64
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P0Y4M24D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	4376737	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	2.61
CY2023Q1	MYMD	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageGrantDateFairValue	2.61
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P0Y3M7D
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	44780	usd
CY2022Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	636658	usd
CY2023Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	550000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39470009	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39470009	shares
CY2023Q1	us-gaap	Liquidation Basis Of Accounting Adoption LiquidationBasisOfAccountingAdoption	Upon any liquidation, dissolution or winding-up of the Company, whether voluntary or involuntary, the each holder shares of the Series F Preferred Stock shall be entitled to receive out of the assets, whether capital or surplus, of the Company an amount per share of Series F Preferred Stock equal to the greater of (A) 125% of the stated value of such share of Series F Preferred Stock (plus any applicable make-whole amount, unpaid late charge or other applicable amount) on the date of such payment and (B) the amount per share such holder would receive if such holder converted such share of Series F Preferred Stock into Common Stock immediately prior to the date of such payment. All shares of capital stock of the Company shall be junior in rank to all shares of Series F Preferred Stock with respect to the preferences as to payments upon the liquidation
CY2023Q1	us-gaap	Long Term Debt Description LongTermDebtDescription	The amortization payments due upon such redemption are payable, at the company’s election, in cash, or subject to certain limitations, in shares of Common Stock valued at the lower of (i) the Conversion Price then in effect and (ii) the greater of (A) a 80% of the average of the three lowest closing prices of the Company’s Common Stock during the thirty trading day period immediately prior to the date the amortization payment is due or (B) the Floor Price (as defined below). For purposes of the Series F Certificate of Designation, the “Floor Price” means the lower of (x) $0.4014 and (y) 20% of the “Minimum Price” (as defined in Rule 5635 of the Rules of the Nasdaq Stock Market) on the date of the Stockholder Approval (subject to adjustment for stock splits, stock dividends, stock combinations, recapitalizations or other similar events) or, in any case, such lower amount as permitted, from time to time, by the Nasdaq Stock Market; provided that if the amount set forth in clause B is the lowest effective price, the Company will be required to pay the amortization payment in cash
CY2023Q1	us-gaap	Convertible Preferred Stock Terms Of Conversion ConvertiblePreferredStockTermsOfConversion	The Series F Preferred Stock cannot be converted to Common Stock if the holder and its affiliates would beneficially own more than 4.99% or 9.99% at the election of the holder of the outstanding Common Stock. However, any holder may increase or decrease such percentage to any other percentage not in excess of 9.99% upon notice to us, provided that any increase in this limitation will not be effective until 61 days after such notice from the holder to us and such increase or decrease will apply only to the holder providing such notice
CY2023Q1	us-gaap	Derivative Liability Fair Value Of Collateral DerivativeLiabilityFairValueOfCollateral	100000	usd
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	39470009	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	39470009	shares
CY2022Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	93233	usd
CY2022Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	5.98
CY2022Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	2.99
CY2023Q1	MYMD	Warrant Expenses Incurred WarrantExpensesIncurred	0	usd
CY2022Q1	MYMD	Warrant Expenses Incurred WarrantExpensesIncurred	0	usd
CY2023Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	1	pure
CY2023Q1	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.03	pure
CY2023Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	10281	usd
CY2022Q1	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	8750	usd

Files In Submission

Name	View Source	Status
FilingSummary.xml	Edgar Link	unprocessable
0001493152-23-017488-index-headers.html	Edgar Link	pending
0001493152-23-017488-index.html	Edgar Link	pending
0001493152-23-017488.txt	Edgar Link	pending
0001493152-23-017488-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
mymd-20230331.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
mymd-20230331_cal.xml	Edgar Link	unprocessable
mymd-20230331_def.xml	Edgar Link	unprocessable
mymd-20230331_lab.xml	Edgar Link	unprocessable
mymd-20230331_pre.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa

2023 Q2 Form 10-Q Financial Statement

#000149315223017488 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA TNF Pharmaceuticals, Inc. Stock $tnfa

2023 Q2 Form 10-Q Financial Statement

#000149315223017488 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TNFA
TNF Pharmaceuticals, Inc. Stock $tnfa